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Disorders of the hepatobiliary system are relatively common extraintestinal manifestations of inﬂammatory bowel disease (IBD).
These disorders are sometimes due to a shared pathogenesis with IBD as seen in primary sclerosing cholangitis (PSC) and small-
duct primary sclerosing cholangitis (small-duct PSC). There are also hepatobiliary manifestations such as cholelithiasis and portal
vein thrombosis that occur due to the eﬀects of chronic inﬂammation and the severity of bowel disease. Lastly, medications used
in IBD such as sulfasalazine, thiopurines, and methotrexate can adversely aﬀect the liver. It is important to be cognizant of these
disorders as some do have serious long-term consequences. The management of these disorders often requires the expertise of
multidisciplinary teams to achieve the best outcomes.
1.Introduction
Inﬂammatory bowel disease (IBD) is a chronic immune-
related disorder of the gastrointestinal tract [1]. Disorders
of the liver and biliary tract can occur as extraintestinal
manifestations of IBD. The clinical course of these disorders
does not always correlate with disease activity and can be
independent of the degree of intestinal inﬂammation [2].
The hepatobiliary manifestations in IBD may occur due to a
sharedpathogenesissuchasinprimarysclerosingcholangitis
(PSC) and small-duct primary sclerosing cholangitis (small-
duct PSC). There are also hepatobiliary manifestations such
as cholelithiasis and portal vein thrombosis that occur due
to the eﬀects of chronic inﬂammation and the severity of
bowel disease (see Table 1). Medications used in IBD such
as sulfasalazine, thiopurines, and methotrexate can also have
adverse eﬀects on the liver.
The goal of this paper is to highlight the common and
some of the less common hepatobiliary manifestations of
IBD as these are very important extraintestinal manifesta-
tions of the disease.
2. PrimarySclerosingCholangitis (PSC)
Primary sclerosing cholangitis (PSC) is a chronic ﬁbro-
proliferative disorder of the biliary tree that frequently leads
to hepatic failure and death in untreated patients [3, 4].
It aﬀects both young and middle-aged patients especially
thosewithunderlyinginﬂammatoryboweldisease(IBD)[5].
Smith et al. ﬁrst described the association between PSC and
IBD. PSC is the most common hepatobiliary disorder associ-
ated with IBD [6, 7]. The natural course of PSC is varied. It
typically manifests as a progressive inﬂammatory state with
resultant obliterative ﬁbrosis and destruction of both the
intra- and extrahepatic biliary tree. These changes eventually
lead to the development of liver cirrhosis and failure [8]. The
prevalence of PSC in IBD is such that approximately 70–80%
of patients with PSC have IBD. Between 1.4–7.5% of patients
with IBD will develop PSC at some point during the course
of their disease [9]. The median age of diagnosis of PSC
is approximately 40 years of age [3]. In a descriptive study
looking at the natural history of PSC and IBD in pediatric
patients, the median age of diagnosis of IBD and PSC was
13 and 14 years of age, respectively. This study also showed
that the time from the development of symptoms of IBD to
the diagnosis of PSC was 2.3 months [4]. There is a male
predominance with this disease and a higher prevalence in
patients with Ulcerative colitis (UC) as compared to those
with Crohn’s disease (CD) [3, 4]. The diagnosis of PSC may
precede that of IBD but the converse is also known to occur.
In the study by Faubion et al, 11% of pediatric patients with
PSC had asymptomatic IBD at the time of diagnosis [4].
The etiology and pathogenesis of PSC still remains un-
clear. There have been several genetic factors linked with2 Gastroenterology Research and Practice
Table 1: Liver disorders in inﬂammatory bowel disease.
Ulcerative colitis Crohn’s disease
More common
Primary sclerosing cholangitis (PSC) Gallstones
Small-duct PSC Medication-associated liver disease
Autoimmune hepatitis/PSC overlap Fatty liver
Medication-associated liver disease
Fatty liver
Less common Gallstones Primary sclerosing cholangitis (PSC)
Small-duct PSC
Rare
Portal vein thrombosis Portal vein thrombosis
Liver abscess Liver abscess
Granulomatous hepatitis Granulomatous hepatitis
a susceptibility to this disorder, and these include HLA-B8,
HLA-DRB1∗0301(DR3), HLA-DRB3∗0101(DRw52a), and
HLA-DRB1∗0401(DR4) [10, 11]. There are also a variety of
autoantigens that have been detected in patients with PSC
such as antinuclear antibodies (ANA) in 24–53%, smooth
muscle antibodies (SMA) in 13–20%, and antiperinuclear
cytoplasmic antibody (pANCA) in 65–88% of patients [12–
15]. The coexistence of PSC and IBD represents a distinct
clinical phenotype as compared with IBD patients without
PSC. Studies have shown that patients with coexisting PSC
and IBD have a higher incidence of rectal sparing, backwash
ileitis, pancolitis, colitis-associated neoplasia, and poorer
survival hence the term PSC-IBD [16–18]. The clinical
presentation of PSC is often varied, and most patients are
asymptomatic at diagnosis. Clinical features of those with
symptoms include fatigue, abdominal pain, pruritus, jaun-
dice, and weight loss. The biochemical parameters are con-
sistent with cholestasis and characteristically show a marked
elevation of the serum alkaline phosphatase and abnormal
liver transaminases [19, 20]. Radiological evaluation is piv-
otal in the diagnosis of PSC. The demonstration of diﬀuse,
multifocal strictures involving the medium- to large- sized
intra- and extrahepatic ductal system forms the basis for the
diagnosis. The use of magnetic resonance cholangiopancre-
aticography (MRCP) provides a sensitive and noninvasive
tool for diagnosis. Endoscopic retrograde cholangiopancre-
aticography (ERCP) is superior in diagnostic accuracy but
has an increased risk for procedure-related complications
[21–25]. The role of liver biopsies in the diagnosis of PSC
is limited and seems to have more relevance in delineating
conditions such as small-duct PSC or pericholangitis in
patients with IBD. This is thought to be part of a disease
spectrum of PSC with features of cholestatic liver disease in
thepresenceofanormalcholangiographicexamination[26].
Patients with PSC are likely to progress to end-stage liver
disease with the attendant complications of portal hyper-
tension such as ascites, varices, and hepatic encephalopathy.
Bleeding from varices may present early in the disease due
to localized vascular damage in the liver and presinusoidal
portalhypertension.Cholangiocarcinomaremainsadreaded
complication of PSC. It is not typically seen in the pediatric
age group but can arise at any stage of PSC. It has an
annualincidenceof0.6–1%andcanpresentasanintraductal
tumor or liver mass [27, 28]. Noninvasive tools have been
developed to determine disease progression and prognosis
in PSC. One such tool is a model developed in The Mayo
Clinic. This model estimates the patient survival in PSC
using reproducible parameters such as age, serum bilirubin,
albumin, aspartate aminotransferase (AST), and the pres-
enceofvaricealbleeding[29].ThemanagementofPSCinthe
presence or absence of IBD still poses a signiﬁcant challenge.
Pharmacological interventions have not been shown to alter
theprogressionofthedisease.Ursodeoxycholicacid(UDCA)
w h i c hi so f t e nu s e di nt h et r e a t m e n to fP S Ch a sb e e n
shown to improve the liver enzyme abnormalities with no
beneﬁcial change in liver histology or survival without liver
transplantation [30]. The largest follow-up series in children
with PSC showed that the overall median survival free of
liver transplantation was 12.7 years. These patients had a
signiﬁcantly shorter survival than expected for their age-
a n dg e n d e r - m a t c h e dp o p u l a t i o n[ 31]. The use of UCDA
in the treatment of patients with PSC has some beneﬁt in
the prevention of colonic neoplasia [32]. The treatment of
choice for end-stage PSC or PSC with cholangiocarcinoma
is orthotopic liver transplantation (OLT). The 5- and 10-
year survival rates following OLT in patients with PSC are
85% and 70%, respectively [33] .T h er e c u r r e n c er a t ei nt h e




It was previously termed as pericholangitis. The presence of
IBD has been speciﬁed by some authors as a prerequisite
for the diagnosis of small-duct PSC [35]. These groups of
patients are thought to represent a spectrum of PSC. The
precise timing of the onset of this disorder in patients with
IBD is unclear but it is very similar to PSC. They typically
p r e s e n tw i t hf e a t u r e sc o n s i s t e n tw i t hP S Cb u th a v ean o r m a l
cholangiogram [26, 36]. In a large multicenter study 80% of
patients with small-duct PSC had IBD diagnosed at followup
or at the time of the diagnosis of liver disease. 78% of these
patients had Ulcerative colitis (UC) while 21% had Crohn’s
colitis [37]. Progression of small duct PSC to PSC can occurGastroenterology Research and Practice 3
in up to 12–23% of patients. There are however no reports
of cholangiocarcinoma in this group of patients unless in
the setting of disease progression to PSC (large duct) [37].
Some patients may require OLT secondary to progression
of the disease; however there remains a risk of recurrence
in the transplanted liver. The diagnosis of small duct PSC
is best achieved with the aid of a liver biopsy, as these pa-
tients characteristically have a normal cholangiographic ex-
amination despite the cholestatic clinical picture [26].
4. PrimarySclerosingCholangitis/Autoimmune
Hepatitis(PSC/AIH)Overlap Syndrome
The diagnostic criteria for this condition are not clearly
validated. It is however suspected in patients who meet
the diagnostic criteria for AIH based on the International
Autoimmune Hepatitis Group. The liver histology in these
patients shows piecemeal necrosis, rosetting, moderate or
severe periportal inﬂammation, and lymphocyte inﬁltration
[38]. This disorder is well described in patients with IBD
especially UC [39]. There is published data that shows pa-
tients with IBD and AIH who subsequently go on to develop
PSC [38, 40, 41]. The signiﬁcance of this relationship with
IBD is still unclear, and the onset of disease can occur
at anytime before or after the diagnosis of IBD. Patients
with PSC/AIH however seem to have beneﬁt from treatment
with immunosuppressive medications and may have a better
prognosis as compared to patients with isolated PSC [40].
5.Cholelithiasis
This is a relatively common entity in patients with IBD. It
is more prevalent in patients with Crohn’s disease (CD) as
compared to those with Ulcerative colitis (UC). The inci-
dence of cholelithiasis in patients with CD ranges from 13
to14% [42–47]. Patients with CD seem to have twice the risk
ofdevelopingcholelithiasisascomparedtoIBD-freecontrols
[48]. The factors associated with the increased development
of cholelithiasis include location of CD disease at diagnosis,
surgery, and extent of ileal resection. Other factors include
the age of the patient (uncommon in children), frequency
of clinical recurrences, length of hospital stay, and the use
o ft o t a lp a r e n t e r a ln u t r i t i o n[ 48]. Patients with CD have
been shown to have reduced gallbladder motility which may
also lead to the development of cholelithiasis [49, 50].
The formation of cholesterol-supersaturated bile, increased
enterohepaticcirculationanddisruption ofbilereabsorption
from a diseased terminal ileum, increases the risk for cho-
lelithiasis in patients with CD [43, 51, 52].
6.Medication-AssociatedLiverDiseasein
InﬂammatoryBowelDisease
6.1. Sulfasalazine. These class of medications are made up
of sulfapyridine (a sulfonamide moiety) linked to 5-amino-
salicylic acid (5-ASA) via an azo bond. Sulfasalazine plays
an important role in both the induction and maintenance
of remission in IBD. Hypersensitivity to sulfasalazine can
induce hepatotoxicity which manifests as elevation of liver
aminotransferases, hyperbilirubinemia, hepatomegaly, fever,
and lymphadenopathy [53, 54]. Studies have shown that the
5-ASA components of the medication can induce both an
acuteandachronichepatitiswhichcanoccurfromanywhere
between 6 days to 1 year after the initiation of treatment, but
the frequency of hepatitis is no diﬀerent between the 5-ASA
alone and sulfasalazine [55–59].
6.2. Thiopurines. Thiopurines (Azathioprine and 6 mercap-
topurine) are immunomodulators used in the treatment of
IBD. Their mechanism of action is based on conversion to
the active metabolite 6-thioguanine [60]. Hepatotoxicity can
occur with the use of Azathioprine (AZA) or 6-mercap-
topurine (6-MP) due to the eﬀect of another metabolite, 6
methylmercaptopurine (6-MMP) [61–64]. The enzyme that
plays a key role in the formation of 6-MMP is thiopurine
s-methyl transferase, and as such a better understanding of
the genetic heterogeneity of this enzyme may be useful in
determining those at risk for hepatotoxicity [61, 64]. The
level of 6-MMP in the blood has been measured in children,
to identify those at risk for drug-related hepatotoxicity
[61]. A much rarer idiosyncratic reaction can occur with
6MP/AZA presenting with features of venoocclusive disease.
This occurs due to damage to the sinusoidal endothelial
cells and occlusion of the central vein [61, 65–67]. This
idiosyncratic reaction can occur at anytime and is indepen-
dent of the duration of medication usage. Discontinuation
of these medications most often leads to reversal of the
acute hepatocellular toxicity; however in some instances the
development of severe cholestasis may not improve despite
withdrawal of the medications [68–70].
6.3. Methotrexate. The mechanism of action of this medica-
tion is based on its ability to inhibit dihydrofolate reductase,
which is an important enzyme in the cell life cycle [71]. The
major storage form of methotrexate in the liver is as a pol-
yglutamate metabolite which is potentially hepatotoxic with
long-term use [72]. There are no clear guidelines for the
monitoring of liver functions in IBD patients on methotrex-
ate, and liver toxicity may become apparent at anytime
with the use of this medication. There are however certain
risk factors for hepatotoxicity with methotrexate, and these
includealcoholuse,obesity,diabetesmellitus,abnormalliver
enzymes at baseline, and a cumulative dose of greater than
1.5 grams [73].
6.4. Biologic Agents. Biologic agents such as Inﬂiximab and
Adalimumab have been associated with hepatotoxicity [74].
These medications interfere with the activity of tumor ne-
crosis factor α (TNF α) which plays a role in hepatocyte
regeneration, hence the possible link with the development
of hepatotoxicity which is still an uncommon side eﬀect with




Animal studies have shown that TNF α plays an important4 Gastroenterology Research and Practice
role in the clearance of hepatitis B from infected hepatocytes
by the inhibition of viral replication and promotion of T-
cell responses [79, 80]. The concern for viral reactivation is
of immense importance as studies have shown a high pre-
valence of hepatitis B or C in adult patients with CD [81].
Due to the grave implications of reactivation of hepatitis B
or C virus in immunosuppressed patients, guidelines have
been proposed for the routine screening of patients for these
viruses before starting biologic agents [82].
7. Less Common LiverDisorders in
InﬂammatoryBowelDisease
7.1. Portal Vein Thrombosis. This is a relatively rare but sig-
niﬁcant thromboembolic complication of IBD. Patients with
IBD are at risk for the development of venous thrombosis.
Patients with IBD also have elevated platelet counts, ﬁbrino-
gen, factor V and VIII levels. There is also a concomitant
decrease in antithrombin III levels. The presence of chronic
bowel inﬂammation is also a risk factor for thrombosis in
these patients [83]. Portal vein thrombosis is more likely to
occur in the postoperative setting and has been reported in
patients with UC after restorative proctocolectomy [84–87].
7.2. Budd Chiari Syndrome. There are published case reports
of Budd Chiari syndrome occurring in patients with IBD
[88, 89]. This is a thromboembolic phenomenon that can
occur at baseline in patients with UC but in the setting
of an acute ﬂare the risk is up to eight times higher [90].
The perioperative period is also a signiﬁcant risk period for
thromboembolism.
7.3. Fatty Liver. Sonographic evidence of fatty liver is not an
uncommonﬁnding inpatientswithIBDwithaprevalenceof
upto35%inarecentstudyof511IBDpatients[46].Patients
with fatty liver often have no symptoms related to the liver;
however there is reported correlation between the severity of
colitis and fatty liver changes in patients with IBD especially
UC [91]. The timing of the onset of fatty liver in patients
with IBD is still unclear. Current therapy is targeted towards
the treatment of the bowel disease and improving the overall
nutritional status of the patient.
7.4. Granulomatous Hepatitis. This is a rare occurrence
found on liver histology in patients with IBD and is usually
seen secondary to treatment with sulfasalazine. It is said to
occur in less than 1% of patients [92]. It can also be seen
with other non-IBD conditions such as malignancies or in-
fections.
8. Conclusion
Hepatobiliary manifestations do occur in IBD and may have
various etiopathogenetic origins. These disorders vary with
regard to the degree of severity ranging from the more
complex disorders such as PSC to the potentially less se-
veremanifestationsuchascholelithiasis.Itishoweverofcrit-
ical importance to remain vigilant for subtle manifestations
of these disorders so as to institute appropriate care which
may require an interdisciplinary approach involving mul-
tiple subspecialty teams such as general surgery, colorectal
surgery, and transplant surgery.
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IBD: Inﬂammatory bowel disease,
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